On Friday, Soleno Therapeutics Inc (NASDAQ: SLNO) opened higher 5.77% from the last session, before settling in for the closing price of $54.63. Price fluctuations for SLNO have ranged from $26.38 to $59.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -77.18% at the time writing. With a float of $30.91 million, this company’s outstanding shares have now reached $31.68 million.
The firm has a total of 42 workers. Let’s measure their productivity. In terms of profitability, gross margin is 57.25%, operating margin of -3995.07%, and the pretax margin is -3806.27%.
Soleno Therapeutics Inc (SLNO) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Soleno Therapeutics Inc is 28.31%, while institutional ownership is 78.34%. The most recent insider transaction that took place on Oct 21 ’24, was worth 51,416,038. Before that another transaction happened on Oct 07 ’24, when Company’s Rule 144 Affiliate proposed sale 2,522,751 for $49.63, making the entire transaction worth $125,204,132.
Soleno Therapeutics Inc (SLNO) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.33 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.26) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -77.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 24.34% growth over the previous five years of trading.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Check out the current performance indicators for Soleno Therapeutics Inc (SLNO). In the past quarter, the stock posted a quick ratio of 17.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.31, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Analysing the last 5-days average volume posted by the [Soleno Therapeutics Inc, SLNO], we can find that recorded value of 0.52 million was better than the volume posted last year of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 56.69%. Additionally, its Average True Range was 2.49.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 89.91%, which indicates a significant increase from 78.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.21% in the past 14 days, which was lower than the 53.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $53.17, while its 200-day Moving Average is $47.00. Now, the first resistance to watch is $58.93. This is followed by the second major resistance level at $60.09. The third major resistance level sits at $62.24. If the price goes on to break the first support level at $55.63, it is likely to go to the next support level at $53.48. Now, if the price goes above the second support level, the third support stands at $52.32.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
There are currently 43,117K shares outstanding in the company with a market cap of 2.63 billion. Presently, the company’s annual sales total 0 K according to its annual income of -38,990 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -76,620 K.
